In vitro phytochemical, antioxidant activity and antimycobacterial potentials of selected medicinal plants commonly used for respiratory infections and related symptoms in the Limpopo Province, South Africa.

Publication date: Jul 09, 2025

The emergence of drug resistance among Mycobacterium tuberculosis (Mtb) strains, coupled with the detrimental side effects linked to tuberculosis (TB) treatment, underscores the persistence of TB as a significant clinical and public health concern in South Africa, thereby necessitating ongoing research in drug discovery. The use of medicinal plants for the treatment of TB has garnered increasing attention, especially in countries where a significant portion of the population relies on traditional medicine as a primary form of healthcare. The crude extracts from nine medicinal plants were investigated for antimycobacterial activity. Phytochemical profiling and qualitative antioxidant activity were assessed using thin layer chromatography. The 2,2-Diphenyl-1-picrylhydrazyl radical scavenging assay was used for quantitative antioxidant analysis. The broth microdilution assay was used to determine the antimycobacterial activity of the plant extracts and rifampicin against Mycobacterium smegmatis (ATCC 1441). Sodium dodecyl polyacrylamide gel electrophoresis was used to qualitatively evaluate the protein profile of M. smegmatis. The growth response of M. smegmatis to both inhibitors (rifampicin and plants extracts) was assessed through growth kinetics assays. Phytochemical profiling revealed that all plants contained various phytoconstituents in differing concentrations. Additionally, the plants exhibited relatively low antioxidant activity, as indicated by their IC values. Rosmarinus officinalis and Zanthoxylum capense demonstrated inhibitory effects on the growth of M. smegmatis with a minimum inhibitory concentration of 0. 625 mg/ml. The time-kill assays indicate that the plant extracts including those of Gardenia volkensii, Citrus lemon, Croton gratissimus and Clerodendrum glabrum exhibited greater growth reduction than rifampicin. Sodium dodecyl polyacrylamide gel electrophoresis profiles revealed distinct patterns of M. smegmatis proteins. Protein profiles suggest that plant extracts, like rifampicin, affect bacterial protein synthesis. The results of this study indicate that the plants do not have potent free radical scavenging capabilities. Nevertheless, they exhibited antimycobacterial properties, notably impacting protein synthesis.

Open Access PDF

Concepts Keywords
Antimycobacterial Antioxidant activity
Citrus Mycobacterium tuberculosis
Increasing Phytochemical
Limpopo Protein profile
Picrylhydrazyl

Semantics

Type Source Name
disease MESH respiratory infections
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease IDO assay
drug DRUGBANK Rifampicin
disease IDO protein
pathway REACTOME Reproduction
disease MESH infections
disease IDO infectious agent
disease IDO history
disease IDO host
pathway REACTOME Immune System
disease IDO pathogen
disease IDO infection
disease MESH inflammation
drug DRUGBANK Isoxaflutole
disease MESH oxidative stress
drug DRUGBANK Isoniazid
drug DRUGBANK Pyrazinamide
disease IDO immunodeficiency
disease MESH COVID 19
disease IDO country
drug DRUGBANK Water
drug DRUGBANK Medical air
disease IDO reagent
drug DRUGBANK Sodium carbonate
drug DRUGBANK Aluminum chloride
drug DRUGBANK Ethanol
drug DRUGBANK Quercetin
drug DRUGBANK Formic Acid
disease MESH bacterial infections
disease MESH asthma
pathway KEGG Asthma
drug DRUGBANK Coenzyme M
drug DRUGBANK Ascorbic acid
drug DRUGBANK Glycerin
drug DRUGBANK Dextromethorphan
drug DRUGBANK Methyl isocyanate
drug DRUGBANK Ademetionine
disease IDO bacteria
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Aspartame
drug DRUGBANK Urea
drug DRUGBANK Acetic acid
drug DRUGBANK L-Phenylalanine
disease IDO bactericidal
drug DRUGBANK Albendazole
drug DRUGBANK Phenol
disease IDO susceptibility
drug DRUGBANK L-Valine
drug DRUGBANK Trestolone
pathway REACTOME Killing mechanisms
disease IDO bacteriostatic
pathway KEGG Metabolic pathways
disease MESH death
disease IDO colony
drug DRUGBANK Nitazoxanide
disease MESH drug interactions
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Ethionamide
drug DRUGBANK Dimethyl sulfone
disease MESH Co infection
disease IDO virulence
disease MESH Drug induced liver injury
disease MESH atherosclerosis
drug DRUGBANK Methylergometrine
drug DRUGBANK Citrus bioflavonoids
disease MESH Mycobacterium infections
drug DRUGBANK Methionine

Original Article

(Visited 13 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *